Marica Meroni

Milan, 20122, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 81 publications

The I148M PNPLA3 Variant Forces Progressive Portal MASLD by Spatially Perturbing Metabolic Pathways Across Liver Zones.

The I148M PNPLA3 Variant Forces Progressive Portal MASLD by Spatially Perturbing Metabolic Pathways Across Liver Zones.

Journal: International journal of molecular sciences

Published: December 23, 2025

Fibulin-3 as a reliable biomarker of fibrosis in obese subjects with metabolic dysfunction-associated steatotic liver disease.

Fibulin-3 as a reliable biomarker of fibrosis in obese subjects with metabolic dysfunction-associated steatotic liver disease.

Journal: Annals of hepatology

Published: November 25, 2025

New Challenges in the Study of Liver Diseases: From Molecular Pathogenesis to Therapeutic Approaches (3rd Edition).

New Challenges in the Study of Liver Diseases: From Molecular Pathogenesis to Therapeutic Approaches (3rd Edition).

Journal: Biomedicines

Published: October 29, 2025

Hepatic Zonation in MASLD: Old Question, New Challenge in the Era of Spatial Omics.

Hepatic Zonation in MASLD: Old Question, New Challenge in the Era of Spatial Omics.

Journal: International journal of molecular sciences

Published: September 25, 2025

The KLB rs12152703 variant confers protection against hepatic inflammation in patients with MASLD by boosting Klotho-beta expression.

The KLB rs12152703 variant confers protection against hepatic inflammation in patients with MASLD by boosting Klotho-beta expression.

Journal: JHEP reports : innovation in hepatology

Published: July 14, 2025

Oral lipoteichoic and lipoic acids improve insulin resistance and body composition in porphyria mice on a high-carbohydrate diet.

Oral lipoteichoic and lipoic acids improve insulin resistance and body composition in porphyria mice on a high-carbohydrate diet.

Journal: Journal of physiology and biochemistry

Published: May 22, 2025

A Defective Circulating Mitochondrial Bioenergetics Profile Reflects the Hepatic One and Outlines Genetic MASLD.

A Defective Circulating Mitochondrial Bioenergetics Profile Reflects the Hepatic One and Outlines Genetic MASLD.

Journal: Antioxidants (Basel, Switzerland)

Published: April 11, 2025

Exploring multiorgan mitochondrial dysfunction in the switch toward progressive MASLD in AMLN mice.

Exploring multiorgan mitochondrial dysfunction in the switch toward progressive MASLD in AMLN mice.

Journal: iScience

Published: February 05, 2025

Next Generation Sequencing Allows Identification of a Novel Mutation in the TfR2 Gene and Outperforms the Conventional Diagnostic Techniques.

Next Generation Sequencing Allows Identification of a Novel Mutation in the TfR2 Gene and Outperforms the Conventional Diagnostic Techniques.

Journal: EJHaem

Published: January 27, 2025

Artificial intelligence as a ploy to delve into the intricate link between genetics and mitochondria in patients with MASLD.

Artificial intelligence as a ploy to delve into the intricate link between genetics and mitochondria in patients with MASLD.

Journal: JHEP reports : innovation in hepatology

Published: November 08, 2024

β-Klotho as novel therapeutic target in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A narrative review.

β-Klotho as novel therapeutic target in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A narrative review.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: August 06, 2024

DGAT1 and DGAT2 Inhibitors for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Management: Benefits for Their Single or Combined Application.

DGAT1 and DGAT2 Inhibitors for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Management: Benefits for Their Single or Combined Application.

Journal: International journal of molecular sciences

Published: July 19, 2024

Showing 1-12 of 81

Last Updated: 09/26/2026